IBDEI14M ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18813,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18813,1,3,0)
 ;;=3^Acute Myeloblastic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,18813,1,4,0)
 ;;=4^C92.00
 ;;^UTILITY(U,$J,358.3,18813,2)
 ;;=^5001789
 ;;^UTILITY(U,$J,358.3,18814,0)
 ;;=C92.61^^94^916^9
 ;;^UTILITY(U,$J,358.3,18814,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18814,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,In Remission
 ;;^UTILITY(U,$J,358.3,18814,1,4,0)
 ;;=4^C92.61
 ;;^UTILITY(U,$J,358.3,18814,2)
 ;;=^5001808
 ;;^UTILITY(U,$J,358.3,18815,0)
 ;;=C92.60^^94^916^10
 ;;^UTILITY(U,$J,358.3,18815,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18815,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,Not in Remission
 ;;^UTILITY(U,$J,358.3,18815,1,4,0)
 ;;=4^C92.60
 ;;^UTILITY(U,$J,358.3,18815,2)
 ;;=^5001807
 ;;^UTILITY(U,$J,358.3,18816,0)
 ;;=C92.A1^^94^916^11
 ;;^UTILITY(U,$J,358.3,18816,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18816,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,In Remission
 ;;^UTILITY(U,$J,358.3,18816,1,4,0)
 ;;=4^C92.A1
 ;;^UTILITY(U,$J,358.3,18816,2)
 ;;=^5001814
 ;;^UTILITY(U,$J,358.3,18817,0)
 ;;=C92.A0^^94^916^12
 ;;^UTILITY(U,$J,358.3,18817,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18817,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,Not in Remission
 ;;^UTILITY(U,$J,358.3,18817,1,4,0)
 ;;=4^C92.A0
 ;;^UTILITY(U,$J,358.3,18817,2)
 ;;=^5001813
 ;;^UTILITY(U,$J,358.3,18818,0)
 ;;=C92.51^^94^916^13
 ;;^UTILITY(U,$J,358.3,18818,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18818,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,18818,1,4,0)
 ;;=4^C92.51
 ;;^UTILITY(U,$J,358.3,18818,2)
 ;;=^5001805
 ;;^UTILITY(U,$J,358.3,18819,0)
 ;;=C92.50^^94^916^14
 ;;^UTILITY(U,$J,358.3,18819,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18819,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,18819,1,4,0)
 ;;=4^C92.50
 ;;^UTILITY(U,$J,358.3,18819,2)
 ;;=^5001804
 ;;^UTILITY(U,$J,358.3,18820,0)
 ;;=C94.40^^94^916^17
 ;;^UTILITY(U,$J,358.3,18820,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18820,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
 ;;^UTILITY(U,$J,358.3,18820,1,4,0)
 ;;=4^C94.40
 ;;^UTILITY(U,$J,358.3,18820,2)
 ;;=^5001843
 ;;^UTILITY(U,$J,358.3,18821,0)
 ;;=C94.42^^94^916^15
 ;;^UTILITY(U,$J,358.3,18821,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18821,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Relapse
 ;;^UTILITY(U,$J,358.3,18821,1,4,0)
 ;;=4^C94.42
 ;;^UTILITY(U,$J,358.3,18821,2)
 ;;=^5001845
 ;;^UTILITY(U,$J,358.3,18822,0)
 ;;=C94.41^^94^916^16
 ;;^UTILITY(U,$J,358.3,18822,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18822,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
 ;;^UTILITY(U,$J,358.3,18822,1,4,0)
 ;;=4^C94.41
 ;;^UTILITY(U,$J,358.3,18822,2)
 ;;=^5001844
 ;;^UTILITY(U,$J,358.3,18823,0)
 ;;=D62.^^94^916^18
 ;;^UTILITY(U,$J,358.3,18823,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18823,1,3,0)
 ;;=3^Acute Posthemorrhagic Anemia
 ;;^UTILITY(U,$J,358.3,18823,1,4,0)
 ;;=4^D62.
 ;;^UTILITY(U,$J,358.3,18823,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,18824,0)
 ;;=C92.41^^94^916^19
 ;;^UTILITY(U,$J,358.3,18824,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18824,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,18824,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,18824,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,18825,0)
 ;;=C92.40^^94^916^20
 ;;^UTILITY(U,$J,358.3,18825,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18825,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
